Developing countries

English

Advocating for the rights of people with diabetes in Kyrgyzstan

Kyrgyzstan is a landlocked, largely mountainous country, bordering Kazakhstan, China, Tajikistan and Uzbekistan, and is therefore sometimes referred to as ‘the Switzerland of Central Asia’. But the dramatic beauty of its snow-capped mountains and Alpine gorges hides a terrible potential for destruction: heavy winter snow often leads to spring floods, provoking serious damage in valleys and lowlands.

Redesigning the urban environment to promote physical activity in Southern India

Type 2 diabetes has become the most common metabolic disorder. Its prevalence is growing most rapidly among people in the developing world, primarily due to the rapid demographic and epidemiological changes in these regions. According to IDF, India currently leads the world with an estimated 41 million people with diabetes; this figure is predicted to increase to 66 million by 2025. The diabetes epidemic is more pronounced in urban areas in India, where rates of diabetes are roughly double those in rural areas.

Convivencias: a low-cost model for holistic diabetes education

The objective of holiday camps for children and adolescents with diabetes is to create an environment in which they can learn to embrace their condition and its treatment. Achieving and maintaining good blood glucose control is a key aim; the camps provide excellent opportunities for young people to learn and practise diabetes skills and become familiar with the latest techniques.

Learning the lessons - preventing type 2 diabetes in Nepal

Diabetes has become a significant public health problem in urban Nepal. Studies carried out by the Nepal Diabetes Association in towns and cities throughout the country have revealed a diabetes prevalence of around 15% among people aged 20 years and above, and 19% among people aged 40 years and above. The Association has identified a number of key issues which continue to exacerbate this epidemic in Nepal.

Helping people in times of crisis - mobilizing the power of humanity

Average temperatures are rising due primarily to the release of increased amounts of carbon dioxide and other greenhouse gases through the burning of fossil fuels. This is provoking other changes, including rising sea levels and changes in rainfall. These changes appear to be increasing the frequency and intensity of extreme weather events – floods, droughts, heat waves, hurricanes, and tornados – which have the potential to provoke large-scale human crises.

Addressing inequalities in access through long-term collaboration

Diabetes is a life-long chronic condition. Herein lies one of the major challenges to addressing global inequalities in diabetes care. The costs of insulin and monitoring are often beyond the resources of people with diabetes or their country’s healthcare system. While it is easier to secure temporary price reductions or short-term financial support in the form of donations or grants than it is to find long-term ongoing support, diabetes needs in most countries are not temporary.

Eli Lilly - our vision: support for all people with diabetes


Diabetes monitoring in developing countries

The latest statistics suggest that in the future the majority of people with diabetes will live in developing countries. There are an estimated 35 million people living with diabetes in India, for example, and it is estimated that this number will rise to more than 73 million by 2025. Sadly, it follows that the majority of people with diabetes complications will come from countries whose health systems are not able to deliver quality diabetes care.

Novo Nordisk: changing diabetes care in the developing world


Global access to and availability of insulin

The first practical use of insulin by Banting and Best in 1921 heralded a medical revolution. Overnight, type 1 diabetes went from being a uniformly fatal disease to a manageable disorder. Thousands of people around the world have received awards for surviving 50 years on insulin – some reaching 80 years. Insulin is classified by WHO as an essential drug. Yet, 85 years after its discovery, untold thousands of people with type 1 diabetes and type 2 diabetes in developing countries die each year because they can neither readily access nor afford insulin.

Pages